Compare
Neuronetics, Inc. vs InfuSystem Holdings, Inc vs Xtant Medical Holdings, Inc. vs SI-BONE, Inc.
| Latest fiscal year | Neuronetics, Inc. STIM | InfuSystem Holdings, Inc INFU | Xtant Medical Holdings, Inc. XTNT | SI-BONE, Inc. SIBN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $149.16M | $143.44M | $133.93M | $200.93M |
| Revenue growth (YoY) | +99.2% | +6.4% | +14.2% | +20.2% |
| Gross margin | 48.5% | 56.0% | 62.9% | 79.6% |
| Operating margin | -21.1% | 8.3% | 5.4% | -11.1% |
| Net margin | -26.1% | 4.6% | 3.7% | -9.4% |
| Net income | -$39.00M | $6.63M | $4.97M | -$18.90M |
| EPS (Diluted) | -$0.59 | $0.31 | $0.03 | -$0.44 |
| Operating cash flow | -$20.37M | $24.41M | $12.55M | -$675.0K |
| Free cash flow | -$21.18M | $23.85M | $10.16M | -$9.09M |
| Cash & equivalents | $28.13M | $3.19M | $17.05M | $42.24M |
| Total assets | $141.55M | $100.56M | $94.14M | $238.56M |
| Total liabilities | $115.31M | $43.23M | $43.19M | $61.02M |
| Shareholders' equity | $22.38M | $57.33M | $50.95M | $177.53M |
| Return on year-end equity | -174.3% | 11.6% | 9.8% | -10.6% |
| Shares outstanding | 68.99M | 20.21M | 140.04M | 43.65M |
Revenue, most recent five fiscal years
| Fiscal year | Neuronetics, Inc. | InfuSystem Holdings, Inc | Xtant Medical Holdings, Inc. | SI-BONE, Inc. |
|---|---|---|---|---|
| Latest | $149.16M Ended 2025-12-31 | $143.44M Ended 2025-12-31 | $133.93M Ended 2025-12-31 | $200.93M Ended 2025-12-31 |
| 1 year earlier | $74.89M Ended 2024-12-31 | $134.86M Ended 2024-12-31 | $117.27M Ended 2024-12-31 | $167.18M Ended 2024-12-31 |
| 2 years earlier | $71.35M Ended 2023-12-31 | $125.78M Ended 2023-12-31 | $91.30M Ended 2023-12-31 | $138.89M Ended 2023-12-31 |
| 3 years earlier | $65.21M Ended 2022-12-31 | $109.91M Ended 2022-12-31 | $57.97M Ended 2022-12-31 | $106.41M Ended 2022-12-31 |
| 4 years earlier | $55.31M Ended 2021-12-31 | $102.38M Ended 2021-12-31 | $55.26M Ended 2021-12-31 | $90.15M Ended 2021-12-31 |